Surrey Heartlands

Joint Formulary & PAD

Mycophenolate mofetil - Transplant immunosuppression

You are here : Home > Formulary Search > Mycophenolate mofetil - Transplant immunosuppression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

For EXISTING patients: GPs may continue to prescribe for existing post-transplant patients only. NHS England are looking to repatriate these patients in the future. GPs must not accept any new requests to prescribe for new patients.

 

Status 2

Red
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NHSE
Restrictions / Comments :
Important
For NEW patients: RED drug for post-transplant. Funded by NHS England. GPs should not accept any requests to prescribe post-transplant.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Mycophenolate mofetil
Indication :
Transplant immunosuppression
Group Name :
Keywords :
Shared Care
Brand Names Include :
Arzip, CellCept, Myfortic
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Mycophenolate mofetil is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Transplant immunosuppression.

Committee Recommendations (1)

01 Apr 13 - Not Set
FOR NEW PATIENTS ONLY: The prescribing of mycophenolate mofetil/mycophenolic acid is considered a RED drug post transplant only and is now funded via NHS England for this indication.
FOR EXISTING PATIENTS: GPs should continue to prescribe these treatments. NHS England are looking to repatriate these patients in the future. The Medicines Management Team will be in contact with prescribers when they have more information